Kristie L. Kahl

Treatment with fedratinib may lead to clinically meaningful responses among patients with myelofibrosis who were previously treated with Jakafi, according to an updated analysis of the phase 2 JAKARTA2 study.

Karen, who received her bladder cancer diagnosis in 2010, was faced with a similar challenge after her husband was diagnosed with the same disease just six years later.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with a bladder cancer survivor turned caregiver about the advice she would give her newly-diagnosed self.

While half of women with gynecologic cancer reported experiencing significant fatigue during treatment, only 8% of survivors had symptoms regress without intervention.

Long-term survivors of pediatric neuroblastoma may be at an increased risk for neurocognitive impairment – in particular, due to age at diagnosis and the type of treatment received.

An oncology dietitian offered advice on how to improve appetite and eat healthy before, during and after treatment for gastrointestinal cancers.

A glioblastoma (GBM)-specific app, called OurBrainBank, efficiently collected patients’ symptoms – offering many hope for future research, according to founder Jessica Morris.

Cancer Blows, an event by The Ryan Anthony Foundation, offers hope for many with cancer – all while raising awareness for multiple myeloma.

Many patients wonder why their chemotherapy infusions take so long, so three health care professionals explained the process from start to finish.

In this week’s episode of “CURE Talks Cancer,” we spoke with a melanoma survivor who wishes she knew at diagnosis what her cancer journey would do for her – not to her.

In assessing the quality of family cancer history entered into electronic health records, researchers found that such reporting was suboptimal – highlighting the need to optimize online collection with a provider-free approach.

Increased tumor mutation burden (TMB), which is associated with more inflammation, may be a factor in determining which patients with lung cancer are at higher risk for depression.

In the second part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him about the past, present and future of the myeloma landscape.

In the first part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him on the current initiatives and resources available to patients.

Routine use of prophylactic radiotherapy in patients with malignant pleural mesothelioma is unnecessary following a chest wall procedure, according to multicenter, open-label, phase 3, randomized controlled trial findings published in the Journal of Clinical Oncology.

Maintenance therapy with defactinib failed to improve survival following front-line chemotherapy in patients with merlin-low malignant pleural mesothelioma, according to results from the phase 2 COMMAND trial.

A novel imaging test developed at UT Southwestern may help to determine which patients with kidney cancer would benefit from treatment with immunotherapy.

While advances have been made in the treatment landscape of hepatocellular carcinoma, researchers are now looking into the optimal sequence for which patients should be treated.

The Food and Drug Administration approved Kanjinti, a biosimilar to the US-licensed Herceptin, marking it the fifth of its kind.

An expert discusses the exciting approaches under investigation in mantle cell lymphoma and insight into where future research should focus.

Treatment with lisocabtagene maraleucel, also known as liso-cel, demonstrated clinical activity and appeared tolerable among patients with relapsed/refractory mantle cell lymphoma.

The Food and Drug Administration approved Keytruda monotherapy and in combination with chemotherapy for the front-line treatments of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma.

A practice improvement project at the Mayo Clinic helped to increase attention to family health history and identify those at risk for cancer.

The addition of Venclexta to Gazyva induced prolonged progression-free survival – or the time from treatment to disease worsening – among patients with previously untreated chronic lymphocytic leukemia.

In this week’s episode, we spoke with a patient and his doctor about genomic testing and how it can change treatment outcomes for patients with cancer.

The Food and Drug Administration granted a fast track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.

The Food and Drug Administration revealed its pilot program, designed to assist oncologists and patients requesting access to unapproved therapies in the cancer space.

After progressing on prior therapy, 44% of patients with locally advanced or metastatic urothelial cancer who were treated with enfortumab vedotin demonstrated a response to treatment, according to phase 2 study findings.

The addition of Kisqali to standard-of-care endocrine therapy significantly improved overall survival for premenopausal women with advanced HR-positive/HER2-negative breast cancer compared with endocrine therapy alone.

The phase 3 POLO trial is the first randomized study to establish a biomarker-driven approach in the treatment of metastatic pancreatic cancer.